These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36225582)

  • 1. Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy.
    Zhang L; Chen C; Chai D; Li C; Kuang T; Liu L; Dong K; Deng W; Wang W
    Front Pharmacol; 2022; 13():1018411. PubMed ID: 36225582
    [No Abstract]   [Full Text] [Related]  

  • 2. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
    Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Li C; Xia Z; Li A; Meng J
    Ann Transl Med; 2020 Dec; 8(24):1655. PubMed ID: 33490167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
    Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Jin Q; Chai D; Kuang T; Li C; Guan Y; Liu L; Wang W; Deng W
    Front Pharmacol; 2022; 13():937874. PubMed ID: 36110546
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
    Deng R; Zhang H; Li Y; Shi Y
    J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis.
    Rizzo A; Santoni M; Mollica V; Ricci AD; Calabrò C; Cusmai A; Gadaleta-Caldarola G; Palmiotti G; Massari F
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
    Dar S; Merza N; Qatani A; Rahim M; Varughese T; Mohammad A; Masood F; Reza FZ; Wan S; Almas T
    Ann Med Surg (Lond); 2022 Jun; 78():103752. PubMed ID: 35600176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
    Okuyama Y; Hatakeyama S; Numakura K; Narita T; Tanaka T; Miura Y; Sasaki D; Noro D; Tokui N; Okamoto T; Yamamoto H; Narita S; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    BJUI Compass; 2022 Mar; 3(2):154-161. PubMed ID: 35474728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors: A Meta-analysis.
    Cao X; Wang Y; Huang W; Li P; Guo C; Li Y
    Am J Clin Oncol; 2023 Apr; 46(4):142-149. PubMed ID: 36872516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer.
    Zhang L; Kuang T; Chai D; Deng W; Wang P; Wang W
    Int Immunopharmacol; 2023 Jun; 119():110200. PubMed ID: 37099942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
    Li M; Zeng C; Yao J; Ge Y; An G
    Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
    Zhang F; Liu Z; Liang J; Zhang F; Wu K; Zhou C; Lu Y; Wang X
    Clin Transl Oncol; 2020 Oct; 22(10):1750-1761. PubMed ID: 32086783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.